File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders

TitleOphthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders
Authors
Chau, CYCChow, LLWSridhar, SShih, KC
KeywordsAutoimmune disorders
COVID-19
Inflammatory eye disease
Ophthalmic considerations
Pandemic
Issue Date2021
PublisherSpringer (part of Springer Nature): Fully open access journals - CC BY-NC. The Journal's web site is located at https://link.springer.com/journal/40123
Citation
Ophthalmology and Therapy, 2021, v. 10, p. 201-209 How to Cite?
DOI: http://dx.doi.org/10.1007/s40123-021-00338-1
AbstractThe global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies.
Persistent Identifierhttp://hdl.handle.net/10722/297671
ISSN
2193-8245
2021 Impact Factor: 4.927
2020 SCImago Journal Rankings: 1.189
PubMed Central ID
PMC7936587
ISI Accession Number ID
WOS:000625727700002

 

DC FieldValueLanguage
dc.contributor.authorChau, CYC-
dc.contributor.authorChow, LLW-
dc.contributor.authorSridhar, S-
dc.contributor.authorShih, KC-
dc.date.accessioned2021-03-23T04:20:08Z-
dc.date.available2021-03-23T04:20:08Z-
dc.date.issued2021-
dc.identifier.citationOphthalmology and Therapy, 2021, v. 10, p. 201-209-
dc.identifier.issn2193-8245-
dc.identifier.urihttp://hdl.handle.net/10722/297671-
dc.description.abstractThe global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies.-
dc.languageeng-
dc.publisherSpringer (part of Springer Nature): Fully open access journals - CC BY-NC. The Journal's web site is located at https://link.springer.com/journal/40123-
dc.relation.ispartofOphthalmology and Therapy-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAutoimmune disorders-
dc.subjectCOVID-19-
dc.subjectInflammatory eye disease-
dc.subjectOphthalmic considerations-
dc.subjectPandemic-
dc.titleOphthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders-
dc.typeArticle-
dc.identifier.emailChow, LLW: llwchow@hku.hk-
dc.identifier.emailSridhar, S: sid8998@hku.hk-
dc.identifier.emailShih, KC: kcshih@hku.hk-
dc.identifier.authorityChow, LLW=rp02683-
dc.identifier.authoritySridhar, S=rp02249-
dc.identifier.authorityShih, KC=rp01374-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s40123-021-00338-1-
dc.identifier.pmid33675508-
dc.identifier.pmcidPMC7936587-
dc.identifier.scopuseid_2-s2.0-85102308192-
dc.identifier.hkuros321751-
dc.identifier.volume10-
dc.identifier.spage201-
dc.identifier.epage209-
dc.identifier.isiWOS:000625727700002-
dc.publisher.placeNew Zealand-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats